 Proto-Oncogene Proteins c-bcl-2
"Proto-Oncogene Proteins c-bcl-2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Membrane proteins encoded by the BCL-2 GENES and serving as potent inhibitors of cell death by APOPTOSIS. The proteins are found on mitochondrial, microsomal, and NUCLEAR MEMBRANE sites within many cell types. Overexpression of bcl-2 proteins, due to a translocation of the gene, is associated with follicular lymphoma.
| Descriptor ID |
D019253
|
| MeSH Number(s) |
D12.644.360.075.718 D12.776.476.075.718 D12.776.624.664.700.169
|
| Concept/Terms |
Proto-Oncogene Proteins c-bcl-2- Proto-Oncogene Proteins c-bcl-2
- Proto Oncogene Proteins c bcl 2
- c-bcl-2, Proto-Oncogene Proteins
- c-bcl-2 Proteins
- c bcl 2 Proteins
- bcl-2 Proto-Oncogene Proteins
- Proto-Oncogene Proteins, bcl-2
- bcl 2 Proto Oncogene Proteins
|
Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins c-bcl-2".
Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins c-bcl-2".
This graph shows the total number of publications written about "Proto-Oncogene Proteins c-bcl-2" by people in this website by year, and whether "Proto-Oncogene Proteins c-bcl-2" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 0 | 1 | 1 | | 1994 | 0 | 3 | 3 | | 1995 | 1 | 1 | 2 | | 1996 | 3 | 2 | 5 | | 1997 | 3 | 4 | 7 | | 1998 | 3 | 3 | 6 | | 1999 | 1 | 2 | 3 | | 2000 | 8 | 3 | 11 | | 2001 | 3 | 4 | 7 | | 2002 | 5 | 4 | 9 | | 2003 | 6 | 7 | 13 | | 2004 | 4 | 3 | 7 | | 2005 | 5 | 2 | 7 | | 2006 | 3 | 4 | 7 | | 2007 | 6 | 3 | 9 | | 2008 | 2 | 6 | 8 | | 2009 | 1 | 2 | 3 | | 2010 | 0 | 2 | 2 | | 2011 | 0 | 3 | 3 | | 2012 | 0 | 2 | 2 | | 2013 | 1 | 0 | 1 | | 2014 | 2 | 2 | 4 | | 2015 | 1 | 1 | 2 | | 2016 | 2 | 1 | 3 | | 2017 | 1 | 4 | 5 | | 2018 | 2 | 1 | 3 | | 2019 | 2 | 1 | 3 | | 2020 | 1 | 0 | 1 | | 2021 | 2 | 2 | 4 | | 2022 | 1 | 2 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Proto-Oncogene Proteins c-bcl-2" by people in Profiles.
-
Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, Ebert BL, Fenaux P, Godley LA, Hasserjian RP, Larson RA, Levine RL, Miyazaki Y, Niederwieser D, Ossenkoppele G, Röllig C, Sierra J, Stein EM, Tallman MS, Tien HF, Wang J, Wierzbowska A, Löwenberg B. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022 09 22; 140(12):1345-1377.
-
Sela Y, Li J, Maheswaran S, Norgard R, Yuan S, Hubbi M, Doepner M, Xu JP, Ho ES, Mesaros C, Sheehan C, Croley G, Muir A, Blair IA, Shalem O, Dang CV, Stanger BZ. Bcl-xL Enforces a Slow-Cycling State Necessary for Survival in the Nutrient-Deprived Microenvironment of Pancreatic Cancer. Cancer Res. 2022 05 16; 82(10):1890-1908.
-
Siddiqui F, Perez Silos V, Karube K, Yasin Goksu S, Nandakumar S, Saygin C, Onajin O, Prabu SS, Gurbuxani S, Arber DA, Tjota M, Segal J, Smith SM, Murga-Zamalloa CA, Venkataraman G. B-cell lymphoma-2 downregulation is a useful feature supporting a neoplastic phenotype in mature T-cell lymphomas. Hum Pathol. 2022 07; 125:48-58.
-
Roychowdhury T, Lu H, Hornsby WE, Crone B, Wang GT, Guo DC, Sendamarai AK, Devineni P, Lin M, Zhou W, Graham SE, Wolford BN, Surakka I, Wang Z, Chang L, Zhang J, Mathis M, Brummett CM, Melendez TL, Shea MJ, Kim KM, Deeb GM, Patel HJ, Eliason J, Eagle KA, Yang B, Ganesh SK, Brumpton B, Åsvold BO, Skogholt AH, Hveem K. Regulatory variants in TCF7L2 are associated with thoracic aortic aneurysm. Am J Hum Genet. 2021 09 02; 108(9):1578-1589.
-
Xie VC, Pu J, Metzger BP, Thornton JW, Dickinson BC. Contingency and chance erase necessity in the experimental evolution of ancestral proteins. Elife. 2021 06 01; 10.
-
Singhal J, Kulkarni P, Horne D, Awasthi S, Salgia R, Singhal SS. Prevention of mammary carcinogenesis in MMTV-neu mice by targeting RLIP. Mol Carcinog. 2021 03; 60(3):213-223.
-
Gocho Y, Liu J, Hu J, Yang W, Dharia NV, Zhang J, Shi H, Du G, John A, Lin TN, Hunt J, Huang X, Ju B, Rowland L, Shi L, Maxwell D, Smart B, Crews KR, Yang W, Hagiwara K, Zhang Y, Roberts K, Wang H, Jabbour E, Stock W, Eisfelder B, Paietta E, Newman S, Roti G, Litzow M, Easton J, Zhang J, Peng J, Chi H, Pounds S, Relling MV, Inaba H, Zhu X, Kornblau S, Pui CH, Konopleva M, Teachey D, Mullighan CG, Stegmaier K, Evans WE, Yu J, Yang JJ. Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia. Nat Cancer. 2021 03; 2(3):284-299.
-
Ludwig LM, Roach LE, Katz SG, LaBelle JL. Loss of BIM in T cells results in BCL-2 family BH3-member compensation but incomplete cell death sensitivity normalization. Apoptosis. 2020 04; 25(3-4):247-260.
-
Menendez-Gonzalez JB, Vukovic M, Abdelfattah A, Saleh L, Almotiri A, Thomas LA, Agirre-Lizaso A, Azevedo A, Menezes AC, Tornillo G, Edkins S, Kong K, Giles P, Anjos-Afonso F, Tonks A, Boyd AS, Kranc KR, Rodrigues NP. Gata2 as a Crucial Regulator of Stem Cells in Adult Hematopoiesis and Acute Myeloid Leukemia. Stem Cell Reports. 2019 08 13; 13(2):291-306.
-
Godfrey JK, Nabhan C, Karrison T, Kline JP, Cohen KS, Bishop MR, Stadler WM, Karmali R, Venugopal P, Rapoport AP, Smith SM. Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2. Cancer. 2019 06 01; 125(11):1830-1836.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|